Agilent Completes Acquisition of BIOVECTRA
20 Septembre 2024 - 5:01PM
Business Wire
Pharmaceutical customers will benefit from a
broader set of specialized CDMO capabilities
Agilent Technologies Inc. (NYSE: A) today announced the company
has completed its acquisition of BIOVECTRA, a Canada-based contract
development and manufacturing organization (CDMO) that specializes
in biologics, highly potent active pharmaceutical ingredients, and
other molecules for targeted therapeutics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240919413644/en/
(Graphic: Business Wire)
All closing conditions are completed, including receipt of
regulatory approvals. BIOVECTRA is now part of Agilent’s
Diagnostics and Genomics Group.
“We are delighted to officially welcome the BIOVECTRA team to
Agilent,” said Agilent President and CEO Padraig McDonnell. “This
acquisition demonstrates our commitment to providing customers the
most advanced capabilities to accelerate their therapeutics
programs, including best-in-class cGMP pharmaceutical
manufacturing.”
With the addition of BIOVECTRA, Agilent will expand its
portfolio of CDMO services, add rapidly growing modalities, and
bring world-class capabilities to support gene editing. Additional
details are available in the news release announcing the
acquisition agreement.
Agilent expects the transaction will be $0.05 dilutive to
non-GAAP earnings per share (EPS) in the first full year after
closing and deliver a double-digit return on invested capital
(ROIC) by year five. Agilent funded the transaction using a mix of
cash on hand and debt financing.
Additional Information FAQs for customers Highlights for
Investors About Agilent’s Oligonucleotide GMP Manufacturing About
BIOVECTRA
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers' most challenging questions. The company generated
revenue of $6.83 billion in fiscal 2023 and employs approximately
18,000 people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Forward Looking Statements
This news release contains forward-looking statements as defined
in the Securities Exchange Act of 1934 and is subject to the safe
harbors created therein. The forward-looking statements contained
herein include, but are not limited to, statements regarding the
capabilities the acquisition brings and the assets’ future uses and
the effects of the transaction on our EPS and future ROIC. These
forward-looking statements involve risks and uncertainties that
could cause Agilent’s results to differ materially from
management’s current expectations. Such risks and uncertainties
include, but are not limited to, unforeseen changes in the strength
of Agilent’s customers’ businesses; unforeseen changes in the
demand for current and new products, technologies, and services;
unforeseen changes in the currency markets; customer purchasing
decisions and timing; and the risk that Agilent is not able to
realize the savings expected from integration and restructuring
activities. In addition, other risks that Agilent faces in running
its operations include the ability to execute successfully through
business cycles; the ability to meet and achieve the benefits of
its cost-reduction goals and otherwise successfully adapt its cost
structures to continuing changes in business conditions; ongoing
competitive, pricing and gross-margin pressures; the risk that its
cost-cutting initiatives will impair its ability to develop
products and remain competitive and to operate effectively; the
impact of geopolitical uncertainties and global economic conditions
on its operations, its markets and its ability to conduct business;
the ability to improve asset performance to adapt to changes in
demand; the ability of its supply chain to adapt to changes in
demand; the ability to successfully introduce new products at the
right time, price and mix; the ability of Agilent to successfully
integrate recent acquisitions; the ability of Agilent to
successfully comply with certain complex regulations; and other
risks detailed in Agilent’s filings with the Securities and
Exchange Commission, including its quarterly report on Form 10-Q
for the fiscal quarter ended July 31, 2024. Forward-looking
statements are based on the beliefs and assumptions of Agilent’s
management and on currently available information. Agilent
undertakes no responsibility to publicly update or revise any
forward-looking statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240919413644/en/
INVESTOR CONTACT: Parmeet Ahuja +1 408-345-8948
Parmeet_Ahuja@agilent.com
MEDIA CONTACT: Sarah Litton +1 408-361-0405
sarah.litton@agilent.com
Agilent Technologies (NYSE:A)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Agilent Technologies (NYSE:A)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024